CTRI/2020/06/026008尚未招募4 期
Evaluation of Efficacy and Safety of Gamma-oryzanol in hyperlipidemia: a Randomized Double Blind Placebo Controlled Trial
AP Organics0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •i.Age between 25 and 60 years
- •ii.Either gender & Attending diabetic clinical at hospital.
- •iii.Fasting serum LDL-Cholesterol > 130 mg/dl.
排除标准
- •i.History of intake of dietary supplements or drugs (Retinoids, Cyclosporine, Phenothiazines) which can increase Plasma lipid level.
- •ii.Evidence of renal disease (S. Creatinine > 1.5mg/ml)
- •iii.Evidence of liver disease (AST/ALT >3 times of normal)
- •iv.Pregnant and lactating mothers and women intending pregnancy
- •v.History of alcohol intake and smoking.
- •vi.Participation in any other clinical trial with in the last 30 days
- •vii.History of intolerance or hypersensitivity Gamma-oryzanol.
- •viii.Any condition which in the opinion of the PI that is significant and can make the patient unsuitable for study or can place it under additional risk, such as intolerance, allergy to Gamma-oryzanol.
研究者
相似试验
尚未招募
4 期
Evaluation of Gamma-oryzanol in Type-2 diabetesCTRI/2020/06/026007AP Organics
招募中
不适用
Clinical research on the efficacy and safety of Gyebutang Granule combined with acupuncture on knee osteoarthritisKCT0003264Semyung University100
尚未招募
不适用
Investigating the Efficacy and Safety of Oroxylum Indicum Extract on Overweight and Obese Subjects: A Randomized Controlled Clinical Trial (A Pilot Study)Overweight,anti-hyperlipidemia effectobesityTCTR20200520001Suranaree University of Technology100
尚未招募
不适用
A prospective study to assess the effectiveness of cage use in patients who need to interbody fusion surgery due to cervical diseaseKCT0005601Yonsei University Health System, Severance Hospital40
进行中（未招募）
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.MedDRA version: 11.0Level: LLTClassification code 10057840Term: <Manually entered code. Term in E.1.1>Major Depressive DisorderEUCTR2008-004642-92-HUInstitut de Recherches Internationales Servier400